BioNTech SE (BNTX) Debt Ratio (2018 - 2025)

BioNTech SE (BNTX) posted Debt Ratio of 0.06 for Q4 2025, up 102.9% sequentially from 0.03 in Q3 2025, and down 41.06% YoY from 0.1 in Q4 2024.

BioNTech SE (BNTX) Debt Ratio (2018 - 2025) Analysis & Trends

BioNTech SE has reported Debt Ratio for 8 years, with the latest figure at 0.06 in Q4 2025.

Quarterly Debt Ratio fell 41.06% year-over-year to 0.06 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.06 (down 41.06% YoY) and the FY2025 annual result came in at 0.06, down 41.06% from the prior year.
Debt Ratio climbed to 0.06 in Q4 2025 per BNTX's latest filing, from 0.03 in the prior quarter.
Over five years, Debt Ratio peaked at 0.1 in Q4 2024 and troughed at 0.01 in Q2 2024.
A 5-year average of 0.03 and a median of 0.02 in 2025 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2024: Debt Ratio tumbled 79.66% in 2023, then surged 388.35% in 2024.
Over 5 years, Debt Ratio stood at 0.09 in 2021, then sank by 60.67% to 0.03 in 2022, then plunged by 41.94% to 0.02 in 2023, then jumped by 388.35% to 0.1 in 2024, then tumbled by 41.06% to 0.06 in 2025.
According to Business Quant data, Debt Ratio over the past three periods registered 0.06, 0.03, and 0.01 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	BioNTech SE	23.54 Bn	5.15 Bn	668.28 Mn	0.06

Download Data